Abstract:
Observing the immune function of patients with malignant tumor has a specific significance in the evaluation of the occurrence and development of cancer and in judging patient prognosis and efficacy of anti-cancer therapy. Tumor-bearing hosts often show dysfunction in cellular immunity. In clinics, we often detect lymphocyte subsets and other immunocytes to evaluate the condition of the patient's immunity. Given the rapid development and cross-penetration of oncology, immunology, molecular biology, and other related disciplines, tumor immunotherapy has now become another important anti-tumor treatment following surgery, radiation therapy, and chemotherapy, and it is also now a new approach in treating cancer. This review focuses on the progress of the immune function of patients with malignant tumors and on the immunotherapy for cancers.